340B PATIENTS Act of 2025
NEUTRALHR4581 (340B PATIENTS Act) is an early-stage bill that codifies existing contract pharmacy access within the 340B drug discount program. It creates no new spending, mandates, or regulatory changes. With only a July 2025 referral to committee and no subsequent action, it has zero near-term market impact. CVS has rallied 16.51% over 30 days to $83.68, but this bill is not a driver of that movement.